FindTrial
Sign In

AZD8205

DRUG3 trials

Sponsors

AstraZeneca AB, AstraZeneca

Conditions

B7-H4-Selected Advanced/Metastatic Endometrial Cancer.Biliary Tract CarcinomaBreast CancerEndometrial CancerOvarian CancerSquamous Non-Small Cell Lung Cancerand squamous non-small cell lung cancer.biliary tract carcinoma

Phase 1

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RecruitingNCT05123482
AstraZenecaBiliary Tract Carcinoma, Breast Cancer, Endometrial Cancer +2
Start: 2021-10-18End: 2027-09-29Target: 460Updated: 2026-03-23
A Phase I/IIa Multi-center, Open-label Master Protocol to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of AZD8205 in Participants with Advanced or Metastatic Solid Malignancies.
RecruitingCTIS2022-502759-70-01
AstraZeneca ABand squamous non-small cell lung cancer., biliary tract carcinoma, breast cancer +2
Start: 2024-02-22Target: 97Updated: 2025-12-22

Phase 3

A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician’s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (Bluestar-Endometrial01)
Not yet recruitingCTIS2024-518777-34-00
AstraZeneca ABB7-H4-Selected Advanced/Metastatic Endometrial Cancer.
Target: 180Updated: 2026-01-27

Related Papers

Abstract 7172: Combination of B7-H4-TOP1i ADC, PD-1/TIGIT bispecific antibody, and PARP inhibition orchestrates angiogenesis suppression and interferon-program activation in a syngeneic mouse model
Cancer Research2026-04-03
Extensive Biotransformation Profiling of AZD8205, an Anti-B7-H4 Antibody-Drug Conjugate, Elucidates Pathways Underlying Its Stability <i>In Vivo</i>
Analytical Chemistry2024-10-1111 citations
Abstract 2947: Preclinical evaluation of a novel B7-H4 targeted antibody-drug conjugate AZD8205 as a single agent and in combination with novel PARP inhibitor and checkpoint blockade
Cancer Research2023-04-04
Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305.
2023-03-0148 citations
Abstract 1765: Discovery and first disclosure of AZD8205, a B7-H4-targeted antibody-drug conjugate utilizing a novel topoisomerase I linker-warhead
Cancer Research2022-06-152 citations
First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced/metastatic solid tumors.
Journal of Clinical Oncology2022-06-0120 citations